Back to Agenda
Clinical Outcome Assessments (COA) Endpoints for Use in Rare and Ultra-Rare Disease Clinical Trials
Session Chair(s)
Adora Ndu, JD, PHARMD
Chief Regulatory Affairs Officer, Bridgebio , United States
This session will explore the challenges and opportunities related to patient-focused clinical outcome assessment (COA) endpoint selection, development and implementation in rare and ultra-rare disease drug development. Panelists from industry, the FDA and instrument development experts will provide insight into the identification and implementation of fit-for-purpose COAs in rare disease trials, including challenges specific to endpoint strategy development and clinical trial design. Relevant case studies will be highlighted and special considerations discussed.
Learning Objective : Describe opportunities and challenges in rare disease drug development; Identify how challenges in rare disease clinical trials may be addressed and overcome; Determine how innovators and patient advocates can work with FDA to promote innovation in this space.
Speaker(s)
Sarrit Kovacs
Clinical Reviewer, Division of Gastrenterology, OII, OND, CDER, FDA, United States
Chad Gwaltney, PHD
President, Gwaltney Consulting, United States
Kate Delaney
Director, Regulatory Patient Engagement and Outcomes Research, BioMarin Pharmaceutical Inc., United States
Have an account?